United States Patent 7,138,524: Scope and Claims for Form I Anhydrous Hydrochloride
What is the single independent claim covering?
US Drug Patent 7,138,524 has a narrow claim set as provided:
- Claim 1: “Form I anhydrous 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid hydrochloride.”
This claim is directed to a specific solid-state form (“Form I”) and a specific composition state (“anhydrous”) of a specific drug substance that is defined by a full chemical name, with hydrochloride salt explicitly required. The claim does not read on polymorphs other than Form I, solvates/hydrates other than anhydrous material, or other salts.
What does the claim require for infringement/coverage?
Claim 1, as written, requires all of the following elements in the accused material:
-
Active substance identity
The material must be the hydrochloride of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid.
-
Salt form
The claim requires the hydrochloride salt. The same free base or a different salt (for example, sulfate, mesylate, etc.) is outside the claim.
-
Crystalline/solid-state form
The material must be “Form I”. This typically means a defined crystalline polymorph with a consistent structural pattern (in practice, tied to X-ray diffraction, DSC, Raman, IR, or other characterization metrics in the specification). Any other polymorphic form is outside the scope unless the other form is proven to fall within the “Form I” definition.
-
Water content / hydration state
The material must be “anhydrous.” Any hydrate or solvated form is outside the scope unless it is not actually hydrated and still qualifies as anhydrous per the patent’s characterization criteria.
How narrow is the scope versus typical salt/polymorph claims?
This claim is more restrictive than broad claims that cover “a pharmaceutically acceptable salt” or “one of several polymorphs.” Here, scope is limited to:
- One named polymorph/form: Form I
- One physical state: anhydrous
- One salt: hydrochloride
- One chemical entity: the fully specified acid derivative with the hydroxydiphenylmethyl piperidine substituent pattern
That restriction matters for freedom-to-operate planning because the main design-around levers are straightforward in principle: use a different solid form or a different salt, provided that the alternative does not fall within Form I’s defined characterization.
Claim chart style scope summary (requirement-by-requirement)
| Claim element |
Exact claim language |
What a product must have |
| Solid-state form |
“Form I” |
Solid matches the patent’s “Form I” definition |
| Hydration state |
“anhydrous” |
No water/solvent content within the patent’s anhydrous definition |
| Salt |
“hydrochloride” |
Chloride salt form of the specified acid |
| Substance identity |
full chemical name |
Same drug substance skeleton and substituents as recited |
| Combinability |
all elements in Claim 1 |
Coverage attaches only if all are satisfied simultaneously |
What is the likely role of “Form I” and “anhydrous” in claim construction?
In patents focused on solid forms, the phrase “Form I” functions as a binding technical definition rather than a marketing label. Practically, the patent specification typically contains one or more characterization methods that define Form I, and those are used to interpret the claim scope. Likewise, “anhydrous” typically corresponds to a tested moisture limit, DSC endotherm absence, lack of hydrate reflections, or measured water content below a threshold.
Even without restating the specification, the claim’s wording creates a direct requirement: an accused material must be both Form I and anhydrous. That dual requirement blocks many common competitors’ approaches such as:
- making a different polymorph (Form II, amorphous, etc.)
- isolating a hydrate or solvate
- switching to another pharmaceutically acceptable salt
What does the claim not cover?
Based on the single provided claim text, Claim 1 does not cover:
- The same drug hydrochloride in other forms (non-Form I polymorphs)
- The same Form I in a hydrated/solvated state
- The anhydrous Form I but as a different salt
- Other crystalline forms that are not “Form I”
- Any mixture unless the mixture contains the claimed solid-state product that meets the “Form I anhydrous” requirement
Practical implications for patent landscape work
1) Landing strategy for generic/switch products
For products aiming to avoid this claim, the primary strategy is to target a different solid-state form or a different salt while still meeting bioequivalence and manufacturing constraints. This is a direct route because the claim is single-form and single-salt limited.
2) Risk drivers in manufacturing and scale-up
Even if a manufacturer targets an alternative, changes in:
- crystallization conditions
- drying endpoints
- atmospheric exposure (moisture uptake)
- milling/grinding (which can induce phase changes)
can trigger formation of a different polymorph or convert to an anhydrous solid. That matters because the claim is defined by state (Form I) and water status (anhydrous). An “off-spec” solid can become a claim risk.
3) Analytical proof points become decisive
With a claim framed as “Form I anhydrous,” litigation and technical assessments usually hinge on whether the accused product can be shown to:
- match the Form I pattern/identity
- meet anhydrous qualification criteria (no hydrate/solvate)
For business decisions, this makes the solid-state characterization plan a core diligence item rather than a peripheral regulatory exercise.
What is the scope in “biosimilars” terms (not applicable) and in “small molecule solid form” terms?
The claim is a small-molecule solid-state claim, not a biologic-style sequence or process claim. The coverage is product-by-product and form-by-form. That keeps the landscape analysis focused on:
- polymorph identity mapping across competitors
- salt form distribution
- stability and conversion pathways among forms
Key comparisons: claim 1 versus typical broader polymorph/salt coverage
| Patent claim style |
Coverage breadth |
Where 7,138,524 claim 1 sits |
| “A pharmaceutically acceptable salt” + “a polymorph” |
very broad |
Broader than typical polymorph-only filings |
| “Polymorphs A-D” (group of forms) |
medium |
Claim 1 is narrower because it names only Form I |
| “Specific form + specific salt + anhydrous” |
narrow |
Claim 1 is this narrowest category |
Key Takeaways
- US Drug Patent 7,138,524 (as provided) has Claim 1 that is explicitly limited to Form I anhydrous hydrochloride of a single fully specified drug substance: 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid hydrochloride.
- Coverage requires all elements simultaneously: Form I, anhydrous, and hydrochloride salt of the specified chemical entity.
- The claim’s narrowness creates clear design-around paths in principle (different polymorph/form, hydrate/solvate, or different salt), but manufacturing controls that could convert solids back to Form I anhydrous become the main risk in practice.
FAQs
-
Does Claim 1 cover hydrates of the hydrochloride?
No. Claim 1 requires “anhydrous.”
-
Does Claim 1 cover other polymorphs of the hydrochloride?
No. Claim 1 requires “Form I.”
-
Would the free base (non-hydrochloride) infringe Claim 1?
No. Claim 1 requires the hydrochloride salt.
-
Does Claim 1 cover solvates of the hydrochloride?
No. Claim 1 requires anhydrous, which excludes solvated forms.
-
Is Claim 1 process-limited (manufacturing steps)?
No. As provided, Claim 1 is a product/form claim defined by the solid-state attributes, not by a manufacturing method.
References
[1] United States Patent 7,138,524. Claim 1 text: “Form I anhydrous 4-[4-[4-(Hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-α,α-dimethylbenzeneacetic acid hydrochloride.”
